普洛藥業(000739.SZ):左氧氟沙星片通過WHO的PQ認證
格隆匯4月7日丨普洛藥業(000739.SZ)公佈,近日,公司控股子公司浙江普洛康裕製藥有限公司收到世界衞生組織(WHO)出具的PQ(預認證)確認函,公司左氧氟沙星片通過了WHO的PQ(預認證)審核,並已在WHO網站公示。
左氧氟沙星是氟喹諾酮類藥物氧氟沙星的左旋光學異構體,體外抗菌活性為氧氟沙星的兩倍。其抗菌作用強,抗菌譜廣,是臨牀抗感染的一線藥物。可用於治療成年人(≥18歲)由敏感細菌引起的感染。
據有關數據統計,左氧氟沙星片2019年和2020年在國內城市公立醫院、縣級公立醫院及鄉鎮衞生院終端銷售金額分別為11.71億元和10.04億元,全球銷售金額分別為5.91億美元和6.06億美元。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.